Pfizer Reports Interim Results of Paxlovid (COVID-19 Oral Antiviral Therapy) in P-II/III EPIC-HR Study for the Treatment of COVID-19

Shots:

• The P-II/III EPIC-HR evaluates Paxlovid vs PBO in non-hospitalized adult patients with COVID-19 who are at high risk of progressing to severe illness
• In an interim analysis, the therapy showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause in patients treated within 3 days of symptom onset. In the overall study population @28day, no deaths were reported in patients who received Paxlovid as compared to 10 (1.6%) deaths in patients who received PBO 
• The company plans to submit the data including an ongoing rolling submission to the US FDA for EUA imminently. If Paxlovid is approved or authorized, it will be first oral antiviral therapy

Click here to­ read the full press release/ article | Ref: Pfizer | Image: Pfizer